Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years, study finds

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.

Read the whole article on Science Daily

More from Science Daily